clofarabine has been researched along with resveratrol in 7 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (resveratrol) | Trials (resveratrol) | Recent Studies (post-2010) (resveratrol) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 10,931 | 241 | 7,998 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Roth, ME; Xie, J | 1 |
| Cho, MK; Choi, YJ; Im, JH; Kim, YB; Lee, SH; Lee, YJ; Nam, HS; Won, SY | 1 |
| Cho, MK; Im, JH; Lee, DM; Lee, SH; Lee, YJ; Nam, HS; Park, JS; Won, SY | 1 |
| Cho, MK; Lee, SH; Lee, YJ; Nam, HS; Oh, MH; Park, IS; Park, JW; Shim, JH | 1 |
| Lee, SH; Lee, YJ | 1 |
| Choi, YJ; Hwang, IS; Kim, SH; Lee, CH; Lee, SH; Lee, YJ; Nam, HS | 1 |
| Fabianowska-Majewska, K; Kaufman-Szymczyk, A; Lubecka, K; Majda, K; Szuławska-Mroczek, A | 1 |
7 other study(ies) available for clofarabine and resveratrol
| Article | Year |
|---|---|
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2016 |
Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Line, Tumor; Cell Proliferation; Chromones; Clofarabine; Cyclin D1; Enzyme Inhibitors; Epithelial Cells; Humans; Mesothelioma; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Resveratrol; Sp1 Transcription Factor; Stilbenes | 2013 |
Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Blotting, Western; Cell Proliferation; Clofarabine; Down-Regulation; Drug Synergism; Heme Oxygenase-1; Humans; Mesothelioma; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Resveratrol; RNA, Small Interfering; Signal Transduction; Stilbenes; Tumor Cells, Cultured | 2012 |
Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53.
Topics: Adenine Nucleotides; Anticarcinogenic Agents; Antineoplastic Agents; Arabinonucleosides; Base Sequence; Cell Line, Tumor; Clofarabine; DNA Primers; G1 Phase; Genes, p53; Humans; Mesothelioma; Oncogene Proteins; Polymerase Chain Reaction; Resveratrol; Stilbenes | 2014 |
Resveratrol and clofarabine induces a preferential apoptosis-activating effect on malignant mesothelioma cells by Mcl-1 down-regulation and caspase-3 activation.
Topics: Adenine Nucleotides; Apoptosis; Arabinonucleosides; Caspase 3; Cell Line, Tumor; Clofarabine; Down-Regulation; Enzyme Activation; Humans; Mesothelioma; Myeloid Cell Leukemia Sequence 1 Protein; Resveratrol; Stilbenes | 2015 |
Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Apoptosis; Arabinonucleosides; bcl-X Protein; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Clofarabine; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Humans; Leupeptins; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mesothelioma; Mesothelioma, Malignant; Myeloid Cell Leukemia Sequence 1 Protein; Resveratrol; RNA Interference; RNA, Messenger; RNA, Small Interfering; Stilbenes | 2014 |
Clofarabine‑phytochemical combination exposures in CML cells inhibit DNA methylation machinery, upregulate tumor suppressor genes and promote caspase‑dependent apoptosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell Line, Tumor; Clofarabine; Cyclin-Dependent Kinase Inhibitor p21; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Resveratrol; Tretinoin | 2019 |